



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Attorney Docket No.: 014058-009041US
Client Ref. No.: 457C4

PATENT

TECH CENTER 1600/2900

FEB 10 2003

RECEIVED

On January 31, 2003
TOWNSEND and TOWNSEND and CREW LLP
By: [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SKEIKY et al.

Application No.: 09/688,672

Filed: October 10, 2000

For: FUSION PROTEINS OF
MYCOBACTERIUM TUBERCULOSIS

Examiner: Swartz, Rodney P.

Art Unit: 1645

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed January 3, 2003, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.